Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
作者信息
Ellingson Benjamin M, Wen Patrick Y, Cloughesy Timothy F
机构信息
UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, Los Angeles, California, USA.
UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, California, USA.
出版信息
Neuro Oncol. 2023 Aug 3;25(8):1548-1549. doi: 10.1093/neuonc/noad085.
Abstract
摘要
相似文献
1
Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
Neuro Oncol. 2023 Aug 3;25(8):1548-1549. doi: 10.1093/neuonc/noad085.
2
Letter concerning "Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival": Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
Neuro Oncol. 2023 Aug 3;25(8):1546-1547. doi: 10.1093/neuonc/noad071.
3
Highlighting the need for reliable clinical trials in glioblastoma.
Expert Rev Anticancer Ther. 2018 Oct;18(10):1031-1040. doi: 10.1080/14737140.2018.1496824. Epub 2018 Jul 12.
4
Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
Neuro Oncol. 2017 Apr 1;19(4):469-474. doi: 10.1093/neuonc/nox030.
5
End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.
Expert Rev Anticancer Ther. 2011 Nov;11(11):1713-7. doi: 10.1586/era.11.164.
6
Incorporation of biomarkers in phase II studies of recurrent glioblastoma.
Tumour Biol. 2015 Jan;36(1):153-62. doi: 10.1007/s13277-014-2960-3. Epub 2014 Dec 23.
7
Bevacizumab in glioblastoma multiforme.
Expert Rev Anticancer Ther. 2012 Jan;12(1):9-18. doi: 10.1586/era.11.179.
8
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.
Neuro Oncol. 2018 Jan 10;20(1):113-122. doi: 10.1093/neuonc/nox144.
9
Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.
Eur J Cancer. 2012 Apr;48(6):896-903. doi: 10.1016/j.ejca.2011.10.027. Epub 2011 Nov 24.
10
Epidermal growth factor receptor vaccination for glioblastoma multiforme.
Neurosurgery. 2011 Feb;68(2):N20-1. doi: 10.1227/01.neu.0000393595.61439.13.
本文引用的文献
1
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Neuro Oncol. 2023 Jun 2;25(6):1017-1028. doi: 10.1093/neuonc/noad002.
2
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
JAMA Oncol. 2023 Feb 1;9(2):266-272. doi: 10.1001/jamaoncol.2022.5985.
3
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
Neuro Oncol. 2022 Aug 1;24(8):1219-1229. doi: 10.1093/neuonc/noac086.
4
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
JAMA Intern Med. 2019 Jul 1;179(7):915-921. doi: 10.1001/jamainternmed.2019.0583.
5
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
JAMA Oncol. 2018 Jun 1;4(6):849-856. doi: 10.1001/jamaoncol.2017.5618.
6
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.
Oncologist. 2017 Jul;22(7):762-767. doi: 10.1634/theoncologist.2017-0152. Epub 2017 Jun 2.
7
A perfect correlate does not a surrogate make.
BMC Med Res Methodol. 2003 Sep 9;3:16. doi: 10.1186/1471-2288-3-16.
8
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Br J Cancer. 2000 Sep;83(5):588-93. doi: 10.1054/bjoc.2000.1316.
Zotero 插件